ENLV

Enlivex Therapeutics

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

Israel

Next Earnings Date

29

Business Summary

Enlivex Therapeutics is a clinical-stage immunotherapy company focused on developing therapies for rebalancing a dysfunctional immune system. Its lead product candidate, Allocetra, is a cell therapy designed to treat life-threatening conditions such as sepsis and solid tumors.

 


Analyze ENLV on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$272

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

15.6

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.54

Next Year EPS Growth Estimate

-$0.32

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-72.70%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze ENLV on TradingView

Gainseekers Quantitative Analysis

Summary

Enlivex Therapeutics is a $272 million market cap biotechnology company currently experiencing unprofitability, as shown by its -$0.54 EPS and -72.70% Return on Equity. The company operates with no debt, reflected in a Debt / Equity ratio of 0. The stock trades at a Price / Book multiple of 15.6.

AI Exposure / Tech Reliance

The provided financial data does not contain any information regarding the company's AI exposure or reliance on specific technologies.

The Bull Case

Analysts see potential upside with a Mean Consensus Target Price of $13.00. The company maintains a clean balance sheet with a Debt / Equity ratio of 0.

The Bear Case

The company is highly unprofitable, with a Return on Equity of -72.70% and an EPS of -$0.54. Furthermore, institutional ownership is extremely low at just 0.80%, indicating a lack of conviction from large investors.

Market Sentiment & Smart Money

Short Interest %

0.20%

Analyst Consensus

2.33

Average Analyst Price Target

$13.00

Institutional Ownership %

0.80%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.